Citations 1
Immunodominant antiviral T cell responses outcompete immuno-subdominant antitumor responses to reduce the efficacy of oncolytic viroimmunotherapy
Vile, Richard G. , Kendall, Benjamin, Liseth, Olivia , Sangsuwannukul, Thanich , Elliott, Natalie , Yerovi, Maria Chiriboga , Thompson, Jill , Swanson, Jack, Rizk, Soha S. , Díaz, Rosa María, Tonne, Jason M., Kendall, Benjamin L. , Vile, Richard G , Rizk, Soha , Díaz, Rosa , Tonne, Jason , Elliott, Natalie , Kendall, Benjamin Luke , Kendall, Benjamin
No container title available | March 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract The paradigm in the field of oncolytic virotherapy proposes that tumor cell killing by an oncolytic virus (OV) culminates in the priming of antitumor CD8 T cells. However, this ignores the impact a highly immunodominant antiviral response against the OV has on the antitumor response which has been weakened by mechanisms of central tolerance. Here, we show that inflammatory Vesicular Stomatitis Virus (VSV) failed to prime an adoptively transferred, or pre-existing, population of tumor-reactive T cells.Combination with αPD1 immune checkpoint blockade therapy improved survival only when VSV expressed tumor associated antigens (TAA). These data show that, in this model, the highly inflammatory OV VSV alone actively outcompetes antitumor immunity. However, we also show that viral expression of a mutant near-self TAA can break central tolerance expanding heteroclitic self-reactive and near-self-reactive T cells, thus overcoming viral immunodominance by promoting tumor-specific T cell proliferation in parallel with expanding antiviral T cells.